These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1063 related articles for article (PubMed ID: 35757715)

  • 1. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
    Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
    Front Immunol; 2022; 13():927153. PubMed ID: 35757715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
    Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Khan AN; Asija S; Pendhari J; Purwar R
    Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.
    Kim SJ; Yoon SE; Kim WS
    Ann Lab Med; 2024 May; 44(3):210-221. PubMed ID: 38205527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
    Huang J; Huang X; Huang J
    Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
    Ding S; Chen R; Wang L; Zu C; Zhou X; Zhang J; Zhang M; Jin A; Wang T; Hu Y
    BMC Cancer; 2023 Nov; 23(1):1055. PubMed ID: 37919691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers.
    Perez A; Al Sagheer T; Nahas GR; Linhares YPL
    Front Immunol; 2024; 15():1412002. PubMed ID: 38779668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity.
    Tan JY; Low MH; Chen Y; Lim FLWI
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
    Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
    Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicities following CAR-T therapy for hematological malignancies.
    Hernani R; BenzaquƩn A; Solano C
    Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
    Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
    Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel treatment strategies for hematological malignancies in the immunotherapy era.
    Imai Y
    Int J Hematol; 2024 Jul; 120(1):3-5. PubMed ID: 38861242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
    Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
    Yang C; Nguyen J; Yen Y
    J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome.
    Zheng N; Long Y; Bai Z; Li J; Wang H; Song DD; Liu HL; Shi JH; Zhao S
    J Transl Med; 2024 Jan; 22(1):58. PubMed ID: 38221609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.
    Zhang X; Zhang H; Lan H; Wu J; Xiao Y
    Front Immunol; 2023; 14():1101495. PubMed ID: 36891310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognizing, defining, and managing CAR-T hematologic toxicities.
    Rejeski K; Subklewe M; Locke FL
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):198-208. PubMed ID: 38066881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T-cell therapy for multiple myeloma.
    Wang Z; Chen C; Wang L; Jia Y; Qin Y
    Front Immunol; 2022; 13():1050522. PubMed ID: 36618390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.
    Yan W; Liu Z; Liu J; Xia Y; Hu K; Yu J
    Biomed Res Int; 2020; 2020():4241864. PubMed ID: 33062678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.